uniQure (NASDAQ:QURE) CEO Matthew Kapusta Sells 6,696 Shares

uniQure N.V. (NASDAQ:QURE) CEO Matthew Kapusta sold 6,696 shares of the company’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $50.00, for a total transaction of $334,800.00. Following the transaction, the chief executive officer owned 519,227 shares of the company’s stock, valued at $25,961,350. This trade represents a 1.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

uniQure Price Performance

uniQure stock opened at $47.51 on Friday. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $3.00 billion, a PE ratio of -13.65 and a beta of 0.98. uniQure N.V. has a 12 month low of $8.73 and a 12 month high of $71.50. The stock has a 50-day moving average price of $27.84 and a two-hundred day moving average price of $23.02.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.03. The company had revenue of $3.56 million for the quarter, compared to analysts’ expectations of $5.21 million. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%. Analysts expect that uniQure N.V. will post -3.64 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Torren Management LLC acquired a new position in shares of uniQure during the fourth quarter valued at about $28,000. IFP Advisors Inc acquired a new position in uniQure during the 4th quarter valued at about $48,000. Smartleaf Asset Management LLC bought a new stake in uniQure during the 4th quarter worth approximately $48,000. CIBC Private Wealth Group LLC bought a new stake in uniQure during the 3rd quarter worth approximately $50,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of uniQure by 42.7% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,027 shares of the biotechnology company’s stock worth $72,000 after purchasing an additional 906 shares during the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on QURE. HC Wainwright reiterated a “buy” rating on shares of uniQure in a report on Thursday, June 18th. Barclays upgraded uniQure from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $25.00 to $65.00 in a research report on Thursday, June 18th. Leerink Partners increased their price target on uniQure from $36.00 to $70.00 and gave the company an “outperform” rating in a research note on Thursday, June 18th. Sanford C. Bernstein lowered uniQure to a “market perform” rating in a research note on Tuesday, March 3rd. Finally, Chardan Capital upped their target price on uniQure from $31.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Twelve investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $61.67.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.